FOXP3 and Familial prostate cancer: Using a transgenic mouse model of prostate cancer, Donkor et al. showed that TGF-β-blockade in Foxp3− T cells resulted in heightened CTL responses and better immune-mediated control of primary and metastatic tumors (93).